Abstract
The prevalence and social cost of respiratory diseases such as lung cancer, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, asthma, silicosis, and pulmonary arterial hypertension are high and some of them have few therapeutic alternatives. The therapy of most of these diseases is based on symptomatic control and not on effective cure. The present proposa…